Drug    DrugBank | All Description Patterns💬 Info on mouse-over

No.	DrugBank	Drug (Description in trials)	KEGG DRUG	KEGG GENES	KEGG PATHWAY On map, Yellow: Drug target genes	Disease ID
1	Tocilizumab	[39] Abatacept, rituximab or tocilizumab; Adalimuab, etanercept, tocilizumab, or abatacept; Corticoids+ tocilizumab 8mg/kg/4 weeks; Decrease tocilizumab, abatacept; Etanercepet, rituximab, abatacept, tocilizumab, sarilumab; Inn-tocilizumab; Intra-articular tocilizumab; Mra (tocilizumab); Mra(tocilizumab); Subcutaneous tocilizumab; Tocilizumab; Tocilizumab (actemra or roactemra); Tocilizumab (actemra); Tocilizumab (actemra®); Tocilizumab (mra-sc); Tocilizumab (tcz); Tocilizumab + glucocorticoids (gcs); Tocilizumab + methotrexate(mtx); Tocilizumab 162 mg; Tocilizumab 162mg/0.9ml jeringa sc; Tocilizumab 162mg/0.9ml sc pfs sc; Tocilizumab 162mg/0.9ml syringe sc; Tocilizumab [roactemra/actemra]; Tocilizumab [roactemra]; Tocilizumab and iv steroids combination; Tocilizumab infusion roacemtra (eu); Tocilizumab injection; Tocilizumab iv; Tocilizumab plus methotrexate; Tocilizumab prefilled syringe; Tocilizumab roche; Tocilizumab sc; Tocilizumab sc 162 mg/0.9 ml disposable auto-injector (ai); Tocilizumab sc 162 mg/0.9 ml pre-filled syringe with safety device (pfs); Tocilizumab sc 162 mg/0.9 ml prefilled syringe with safety device (pfs); Tocilizumab treatment; Tocilizumab+methotrexate(mtx); Tocilizumab, abatacept; Tocilizumabum;	[1] D02596 💬	[1] IL6R 💬	[12] Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor	[18]  2 , 13, 40, 41, 42, 43, 46, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬